SCHEMBL8482322

SCHEMBL8482322

C#CC(C)(O)CCCCn1c(=O)c2c(ncn2COCC)n(C)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 3/20 0.49
▸ LMNA P02545 2/20 0.49
▸ CYP1A2 P05177 2/20 0.49
▸ NFKB1 P19838 2/20 0.49
▸ ACHE P22303 2/20 0.49
▸ PMP22 Q01453 2/20 0.49
▸ BLM P54132 2/20 0.49
▸ ESR1 P03372 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ TNF P01375 4/20 0.46
▸ ADORA2B P29275 6/20 0.43
▸ PDE4B Q07343 2/20 0.43
▸ PDE4C Q08493 2/20 0.43
▸ PDE4D Q08499 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ ADORA2A P29274 2/20 0.42
▸ GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Torbafylline SCHEMBL93832 0.89 PDE4A (0.53) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL8484463 0.88 PDE4A (0.64) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL8484328 0.87 PDE4A (0.62) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL8481575 0.86 PDE4A (0.58) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL8483855 0.85 PDE4A (0.62) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL14507751 0.83 PDE4A (0.61) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL14507749 0.82 PDE4A (0.60) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL7452667 0.82 LMNA (0.48) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL10346512 0.81 PDE4A (0.54) PDE4ALMNACYP1A2NFKB1ACHE
SCHEMBL14507748 0.81 PDE4A (0.58) PDE4ALMNACYP1A2NFKB1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5965555-A TREATMENT AND/OR PROPHYLAXIS OF CEREBROVASCULAR DISORDERS CHARACTERIZED BY DAMAGE CAUSED BY ISCHEMIA AND SUBSEQUENT NECROTIC DESTRUCTION OF NERVE CELLS(NEURONS) HOECHST AKTIENGESELLSCHAFT (DE) 1999-10-12 — — US disclosed
Send feedback